

Damian Tworek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2328614/publications.pdf>

Version: 2024-02-01

32
papers

411
citations

840119

11
h-index

752256

20
g-index

34
all docs

34
docs citations

34
times ranked

867
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease after Lobectomy Due to Non-Small Cell Lung Cancer – A Single-Center Retrospective Study. <i>Advances in Respiratory Medicine</i> , 2021, 89, 247-253.	0.5	4
2	Cord blood hemopoietic cell receptor expression is associated with early life atopic risk and lung function. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1762-1765.	2.7	1
3	Epithelial alarmin levels in exhaled breath condensate in patients with idiopathic pulmonary fibrosis: A pilot study. <i>Clinical Respiratory Journal</i> , 2019, 13, 652-656.	0.6	6
4	<p>Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1611-1631.	0.9	12
5	IL-33 and Its Receptor ST2 after Inhaled Allergen Challenge in Allergic Asthmatics. <i>International Archives of Allergy and Immunology</i> , 2018, 176, 133-142.	0.9	36
6	The association between airway eosinophilic inflammation and IL-33 in stable non-atopic COPD. <i>Respiratory Research</i> , 2018, 19, 108.	1.4	40
7	Epithelial alarmin levels in exhaled breath condensate in patients with idiopathic pulmonary fibrosis. , 2018, , .		0
8	Overexpression of chitotriosidase and YKL-40 in serum and sputum in healthy smokers and patients with chronic obstructive pulmonary disease. , 2018, , .		0
9	Toll-like receptor-induced expression of epithelial cytokine receptors on haemopoietic progenitors is altered in allergic asthma. <i>Clinical and Experimental Allergy</i> , 2017, 47, 900-908.	1.4	12
10	Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. <i>Clinical and Experimental Allergy</i> , 2017, 47, 331-338.	1.4	35
11	Skin condition and its relationship to systemic inflammation in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2017, Volume 12, 2407-2415.	0.9	7
12	Eosinophilic COPD – A Distinct Phenotype of the Disease. <i>Advances in Respiratory Medicine</i> , 2017, 85, 271-276.	0.5	12
13	Expression of activation markers in circulating basophils and the relationship to allergen-induced bronchoconstriction in subjects with mild allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 936-938.e7.	1.5	10
14	Human Hemopoietic Progenitor Cell Toll-like and Thymic Stromal Lymphopoietin Receptor Expression and Function in Allergic Asthmatic Subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB73.	1.5	0
15	IL-25 and IL-33 induce Type 2 inflammation in basophils from subjects with allergic asthma. <i>Respiratory Research</i> , 2016, 17, 5.	1.4	55
16	IL-25 Receptor Expression on Airway Dendritic Cells after Allergen Challenge in Subjects with Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 957-964.	2.5	43
17	Extrabronchial symptoms and late phase reaction enhance the diagnostic value of aspirin bronchial challenge. <i>Postepy Dermatologii I Alergologii</i> , 2015, 6, 431-436.	0.4	1
18	Timing is everything: Targeting IgE to reduce asthma exacerbation risk. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1486-1487.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust. <i>Postepy Dermatologii I Alergologii</i> , 2014, 1, 39-44.	0.4	7
20	Omalizumab in pregnant women treated due to severe asthma: two of good outcomes of pregnancies. <i>Postepy Dermatologii I Alergologii</i> , 2014, 2, 104-107.	0.4	13
21	Oral Steroid-Sparing Effect of Omalizumab in Severe Asthma Patients Treated with Systemic Steroids – the Real-Life Experience From Poland. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB6.	1.5	0
22	Perennial is More Effective than Preseasonal Subcutaneous Immunotherapy in the Treatment of Seasonal Allergic Rhinoconjunctivitis. <i>American Journal of Rhinology and Allergy</i> , 2013, 27, 304-308.	1.0	23
23	MIG (CXCL9), IP-10 (CXCL10) and I-TAC (CXCL11) concentrations after nasal allergen challenge in patients with allergic rhinitis. <i>Archives of Medical Science</i> , 2013, 5, 849-853.	0.4	31
24	Two Patterns of Changes in Nasal Nitric Oxide after Lysine Aspirin Nasal Challenge in Patients with Aspirin-exacerbated Respiratory Disease. <i>American Journal of Rhinology and Allergy</i> , 2012, 26, 428-432.	1.0	2
25	Nasal nitric oxide measurements in the assessment of nasal allergen challenge. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2012, 22, 102-8.	0.6	6
26	The Analysis Of The Correlation Between ER22/23EK Polymorphism Of h-GR/NR3C1 Gene And Occurrence Of Severe Bronchial Asthma In Polish Population. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, AB56-AB56.	1.5	0
27	Changes in CXCL9, CXCL10 and CXCL11 Concentrations after Nasal Allergen Challenge. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, AB126-AB126.	1.5	0
28	The Role Of N363S Polymorphism Of H-GR/NR3C1 Gene In Development Of Non-Severe And Severe Bronchial Asthma In Polish Population. , 2011, , .		0
29	The Bcl I single nucleotide polymorphism of the human glucocorticoid receptor gene h-GR/NR3C1 promoter in patients with bronchial asthma: pilot study. <i>Molecular Biology Reports</i> , 2011, 38, 3953-3958.	1.0	42
30	Changes in Nasal Nitric Oxide After Allergen Challenge - Relation to Nasal Blockage. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, AB103.	1.5	1
31	The Effectiveness of Allergen Immunotherapy Depending on the Regimen on Rhinoconjunctivitis and Asthma Symptoms in Allergy to Grass Pollen.. , 2009, , .		0
32	The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2007, 20, 244-249.	1.1	10